President Donald Trump signed an executive order Thursday that would reclassify marijuana as a less dangerous drug and open new avenues for medical research, a major shift in federal drug policy that inches closer to what many states have done.
The switch would move marijuana away from its current classification as a Schedule I drug, alongside heroin and LSD. Cannabis would instead be a Schedule III substance, like ketamine and some anabolic steroids.
Reclassification by the Drug Enforcement Administration would not make it legal for recreational use by adults nationwide, but it could change how the drug is regulated and reduce a hefty tax burden on the cannabis industry.
Similarly, the Justice Department under Trump's Democratic predecessor, Joe Biden, proposed reclassifying marijuana to a Schedule III substance. Unlike Biden, Trump did not have open encouragement from across his party for the move. Some Republicans have spoken out in opposition to any changes and urged Trump to maintain current standards.
Such a switch typically requires an arduous process, including a public comment period that has drawn tens of thousands of reactions from across the U.S. The DEA was still in the review process when Trump took office in January. Trump's order is expected to speed the process along, though it was not immediately clear how long it might take.
Many states have legalized the recreational use of marijuana for adults or allow it for medical purposes. But U.S. laws have remained stricter, potentially leaving people subject to federal prosecution.
Polling from Gallup shows more Americans back a less restrictive approach: Support for marijuana legalization has grown significantly, from just 36% support in 2005 to 68% last year.
Trump's order also calls for expanded research and access to CBD, a legal and increasingly popular hemp-derived product whose benefits are debated by experts.
More than 20 Republican senators, several of them staunch Trump allies, signed a letter this year urging the president to keep marijuana a Schedule I drug. Led by North Carolina Sen. Ted Budd, the group argued that marijuana continues to be dangerous and that a shift would undermine your strong efforts to Make America Great Again. They argued, too, that marijuana negatively affects users' physical and mental health, as well as road and workplace safety.
The only winners from rescheduling will be bad actors such as Communist China, while Americans will be left paying the bill, the letter said, referring to China's place in the cannabis market.
As for decriminalizing marijuana, Trump has not previously committed to such a move, though he had considered reclassifying it for much of his second term. He once said as a candidate that it should remain a state-by-state issue.
As president, he has made his crusade against other drugs, especially fentanyl, a feature of his second term, ordering U.S. military attacks on Venezuelan and other boats the administration insists are ferrying drugs.
He signed another executive order declaring fentanyl a weapon of mass destruction.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app